NCM
PTGX icon

NEXTBio Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

NEXTBio Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Sell
219,333
-10,286
-4% -$1.07M 12.37% 1
2026
Q1 		$24.2M Hold
229,619
– – 11.24% 2
2025
Q4 		$20.1M Buy
+229,619
New +$18.8M 11.76% 2

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

NEXTBio Capital Management's PTGX Position: Q2 2026 in Review

NEXTBio Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 4.5% in Q2 2026, selling an estimated $1.07M and leaving 219,333 shares worth $26.9M. The position accounts for 12.37% of the portfolio, ranked #1.

NEXTBio Capital Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • NEXTBio Capital Management held 219,333 shares of Protagonist Therapeutics worth $26.9M as of Q2 2026.
  • NEXTBio Capital Management sold 10,286 Protagonist Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Protagonist Therapeutics made up 12.37% of NEXTBio Capital Management's portfolio in Q2 2026, its #1 holding.
  • NEXTBio Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.